Genflow Biosciences PLC (LSE:GENF) CEO Dr Eric Leire spoke to Proactive after releasing final results for calendar year 2022 that show that the UK-based biotechnology company is fully funded for at least the next two years, despite its strong emphasis on R&D.
Leire says that Genflow is "very excited" about the steps its taking to "actively increase" its presence in the US, where it has applied to trade its shares on the OTCQB Venture Market.